NVAX stock holds near 10 dollars as new institutional money arrives

Novavax stock (ISIN US66987V1098) is trading near the 10 dollar mark as of September 4, 2026, with recent data pointing to a mixed picture of fresh institutional buying and sharply lower revenue compared with the prior year.

Institutional investors increase their exposure

According to a same day analysis from MarketBeat dated September 4, 2026, Bank of New York Mellon acquired 849,718 Novavax shares during the second quarter, an investment worth about 8,000,000 dollars and equal to roughly 0.52 percent of the company.

The same MarketBeat overview notes that institutional investors and hedge funds collectively hold about 53.04 percent of NVAX as of the latest filings, underlining that a majority of the float is now in professional hands rather than purely retail ownership.

Recent quarterly figures remain weak year over year

In its most recently reported quarter, Novavax posted adjusted losses of 0.32 dollars per share, a result that came in ahead of analyst expectations but still underscored that the company remains unprofitable; this figure refers to the latest quarter quoted by MarketBeat and sits within the permitted freshness window relative to September 4, 2026.

On the revenue side, the same analysis cites quarterly revenue of 56.7 million dollars, which exceeded consensus forecasts but represented a steep 76.2 percent decline compared with the same quarter a year earlier, illustrating how sharply the company’s top line has contracted as pandemic era vaccine demand has faded.

The combination of a smaller than expected loss and significantly lower revenue highlights the current trade off investors face: cost control and one off items can improve earnings versus expectations, but the underlying business scale is far below the prior year baseline.

Analyst view and valuation metrics

MarketBeat reports that Novavax currently carries an overall analyst rating of Hold, with an average price target of 14.00 dollars compared with a recent share price quoted at 10.34 dollars, implying upside of around 35 percent if the consensus target were to be reached.

The same article notes that shares of Nasdaq listed NVAX opened at 10.34 dollars on the latest trading day referenced in the report, a level that frames the current valuation discussion and matches the analyst comparison used in the 14 dollar average target metric.

Supplementary data from QW Research put Novavax’s market capitalization around 1,300,000,000 dollars, with a price to sales ratio of roughly 1.1 and revenue growth stated at about 64.7 percent for the period covered by that dataset, showing that different time frames can paint a contrasting picture to the steep year over year drop reported for the latest quarter.

Representative product focus: Novavax vaccine portfolio

Novavax is best known for its protein based vaccine portfolio, particularly its Covid 19 vaccine that was developed as a non mRNA alternative during the pandemic and later used as a booster in multiple markets; while current revenue has fallen from peak levels as indicated by the 76.2 percent year over year decline in the latest quarter, the company continues to pursue additional indications and updated formulations to stabilize and grow its franchise over time.

Stock level and investor takeaway

As of the most recent quote snapshot on September 4, 2026, Novavax stock is trading close to 10 dollars per share on Nasdaq, against a backdrop of mixed signals: institutional ownership above 50 percent, an average analyst target of 14 dollars, but a business that remains loss making on an adjusted basis and that has seen quarterly revenue fall from 239.0 million dollars a year ago to 56.7 million dollars in the latest period.